Lumibird Shares Climb to €22.60, Up 88% Over the Year

A Resilient Stock in a Pressured Paris Market

Lumibird is up 1.8% at €22.60 as the broader CAC ALL SHARES index falls during the session. The stock ranks 22nd out of 328 listed values, in a context where the DAX is down 0.77% and the SBF 120 loses 0.47%. A beta of 0.17 reflects a low correlation with market movements, partly explaining the observed disconnection. The one-month volatility is measured at 14.14, a contained level. The price has moved back above the 50-day moving average (€22.32), with a gap of 1.25%. It also performs well above the 200-day MA at €20.89, a shift of 8.19% confirming the medium-term upward trend. The RSI at 50 is strictly neutral, indicating that neither buyers nor sellers dominate in the short term.

Photonics Accelerating, Semi-Annual Schedule in Focus

The latest first-quarter activity update, published on April 29, highlighted two opposing dynamics: the Photonics division grew by 11.3%, driven by Defense and Space, while the Medical division fell by 9.2%. Quarterly revenue amounted to €49.7 million, up 0.7% in published terms and 4.1% at constant exchange rates. At the annual results announcement for 2025 (on January 27, 2026), the company targeted an EBITDA margin above 19% at the group level in 2025, with a goal of over 21% for Medical and 17% for Photonics. The stock maintains a considerable lead over one year, with a gain of 88.33%. However, the performance over three months is almost flat at -0.44%, illustrating the consolidation phase that followed the peak of €25.95 reached on April 20. The next key date on the financial calendar is the publication of the semi-annual 2026 revenue, expected on July 27.